Ticker brief
PALI
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
10
authors 14d
7
crowd 14d
+0.2σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-08 → 2026-10-13 · now +0.00 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -1.06 | 2 | +0.40 |
| @OzmosiHealth | C | · | 2 | +0.15 |
| @BiopharmIQ | B | · | 2 | +0.15 |
| @zohmbastic | C | -2.94 | 1 | +0.40 |
| @BioStocks | C | -1.77 | 1 | +0.25 |
| @PrismMarketView | C | · | 1 | +0.30 |
| @PrismDM | A | -2.76 | 1 | +0.00 |
Recent signals10of 10 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-13 | @OzmosiHealth | +0.00 | Reports presentation of Phase 1 GT-2108 inflammatory-bowel-disease results. | · | tweet ↗ |
| 2026-10-12 | @PrismDM | +0.00 | Reports very early PALI-2108 data from two five-patient, uncontrolled studies and flags Phase 2 as decisive. | · | tweet ↗ |
| 2026-10-12 | @PrismMarketView | +0.30 | Summarizes encouraging tiny open-label PALI-2108 studies while emphasizing major design limitations. | · | tweet ↗ |
| 2026-10-12 | @BiopharmIQ | +0.20 | Summarizes same-day biotech price reactions to clinical catalysts. | · | tweet ↗ |
| 2026-10-12 | @BiopharmIQ | +0.10 | Catalogs opening price moves tied to biotech data releases. | · | tweet ↗ |
| 2026-10-12 | @OzmosiHealth | +0.30 | New data strengthen the Phase 2 rationale for PALI-2108. | · | tweet ↗ |
| 2026-10-12 | @semodough | +0.40 | Five presentations support target engagement, early activity and continued Phase 2 development. | · | tweet ↗ |
| 2026-10-12 | @BioStocks | +0.25 | Reports new clinical and mechanistic data supporting the Phase 2 rationale for PALI-2108. | · | tweet ↗ |
| 2026-10-09 | @semodough | +0.40 | Raymond James initiates PALI at Outperform with a $6 target ahead of 2027 Phase 2 updates. | · | tweet ↗ |
| 2026-10-08 | @zohmbastic | +0.40 | Raymond James initiated Palisade Bio at Outperform with a $6 target. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.